DaVita Inc. (DVA) Income Statement

The revenue trend has moved within a narrow band of roughly 4% to 7% over the ten reported quarters, which is consistent with a non-discretionary treatment base driven by patient volume and reimbursement escalators rather than new market expansion. The deceleration in the most recent quarter, from 5.2% to 4.6%, warrants monitoring to determine whether it reflects normal quarterly variance or an early shift in treatment volumes or commercial mix. Because the reported growth rates are not clearly decomposed into volume, pricing, and acquisition effects in the supplied data, the durability of this growth cannot be fully attributed to any single driver.

The gross margin band reflects a high fixed-cost facility model in which government reimbursement rates limit pricing flexibility, so margin movements likely track labor and pharmaceutical cost pressures more than revenue changes. The dip to 28.3% in 2025Q4 is the clearest sign of cost pressure in the period, and the recovery toward 32% to 33% in 2026 may indicate that labor and supply cost management has improved. Investors should monitor whether the 2026Q3 reading of 31.5% holds, since sustained margins near the lower end of the range would suggest reduced operating cushion.

Operating income has not shown clear evidence of strong operating leverage, as margins fluctuate with gross margin rather than expanding independently through SG&A efficiency. SG&A stayed in a range of roughly $367 million to $472 million per quarter, growing with the revenue base and limiting any incremental margin benefit. The 2026Q3 operating margin contraction to 14.0% suggests that cost growth may be outpacing revenue in the latest period, which investors should watch closely.